CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Ronchi, Cristina L ^a   Sbiera, Silviu ^a   Volante, Marco ^b   Steinhauer, Sonja ^a   Scott Wild, Vanessa ^a   Altieri, Barbara ^a   Kroiss, Matthias ^a   Bala, Margarita ^a   Papotti, Mauro ^b   Deutschbein, Timo ^a   Terzolo, Massimo ^c   Fassnacht, Martin ^a   Allolio, Bruno ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TURIN   (Italy)

^c UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYTOCHROME P450; CYTOCHROME P450 2W1; DOXORUBICIN; ETOPOSIDE; MESSENGER RNA; MITOTANE; STREPTOZOCIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; CYP2W1 PROTEIN, HUMAN; TUMOR PROTEIN;

ADRENAL CORTEX CARCINOMA; ADRENAL GLAND; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; CYP2W1 GENE; DRUG RESPONSE; EMBRYO; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TREATMENT OUTCOME; ADRENAL CORTEX NEOPLASMS; ADRENOCORTICAL CARCINOMA; BIOSYNTHESIS; CLINICAL TRIAL; DRUG EFFECTS; ENZYMOLOGY; GENE EXPRESSION REGULATION; PATHOLOGY;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLANDS; ADRENOCORTICAL CARCINOMA; ANTINEOPLASTIC AGENTS, HORMONAL; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MITOTANE; NEOPLASM PROTEINS;

EID: 84930357123     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0105855     Document Type: Article

References (34)

1. Abiven G, Coste J, Groussin L, Anract P, Tissier F, et al. (2006) Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab 91: 2650-2655. (Pubitemid 44024632)
2. Allolio B, Fassnacht M (2006) Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab 91: 2027-2037. (Pubitemid 43854976)
3. Libe R, Fratticci A, Bertherat J (2007) Adrenocortical cancer: pathophysiology and clinical management. Endocr Relat Cancer 14: 13-28. (Pubitemid 47521719)
4. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, et al. (2008) Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer 113: 3130-3136.
5. Ronchi CL, Kroiss M, Sbiera S, Deutschbein T, Fassnacht M (2014) European Journal of Endocrinology Prize Lecture 2014: Current and evolving treatment options in adrenocortical carcinoma- where do we stand and where do we want to go? Eur J Endocrinol.
6. Karlgren M, Ingelman-Sundberg M (2007) Tumour-specific expression of CYP2W1: its potential as a drug target in cancer therapy. Expert Opin Ther Targets 11: 61-67.
7. Wu ZL, Bartleson CJ, Ham AJ, Guengerich FP (2006) Heterologous expression, purification, and properties of human cytochrome P450 27C1. Arch Biochem Biophys 445: 138-146. (Pubitemid 41821070)
8. Li W, Tang Y, Hoshino T, Neya S (2009) Molecular modeling of human cytochrome P450 2W1 and its interactions with substrates. J Mol Graph Model 28: 170-176.
9. Eun CY, Han S, Lim YR, Park HG, Han JS, et al. (2010) Bioactivation of Aromatic Amines by Human CYP2W1, An Orphan Cytochrome P450 Enzyme. Toxicol Res 26: 171-175.
10. Xiao Y, Guengerich FP (2012) Metabolomic analysis and identification of a role for the orphan human cytochrome P450 2W1 in selective oxidation of lysophospholipids. J Lipid Res 53: 1610-1617.
11. Edler D, Stenstedt K, Ohrling K, Hallstrom M, Karlgren M, et al. (2009) The expression of the novel CYP2W1 enzyme is an independent prognostic factor in colorectal cancer - a pilot study. Eur J Cancer 45: 705-712.
12. Tan BS, Tiong KH, Muruhadas A, Randhawa N, Choo HL, et al. (2011) CYP2S1 and CYP2W1 mediate 2-(3,4-dimethoxyphenyl)-5-fluorobenzothiazole (GW-610, NSC 721648) sensitivity in breast and colorectal cancer cells. Mol Cancer Ther 10: 1982-1992.
13. Gomez A, Karlgren M, Edler D, Bernal ML, Mkrtchian S, et al. (2007) Expression of CYP2W1 in colon tumors: regulation by gene methylation. Pharmacogenomics 8: 1315-1325. (Pubitemid 350162848)
14. Gomez A, Nekvindova J, Travica S, Lee MY, Johansson I, et al. (2010) Colorectal cancer-specific cytochrome P450 2W1: intracellular localization, glycosylation, and catalytic activity. Mol Pharmacol 78: 1004-1011.
15. Karlgren M, Gomez A, Stark K, Svard J, Rodriguez-Antona C, et al. (2006) Tumor-specific expression of the novel cytochrome P450 enzyme, CYP2W1. Biochem Biophys Res Commun 341: 451-458. (Pubitemid 43152125)
16. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB (2005) Expression patterns of mouse and human CYP orthologs (families 1-4) during development and in different adult tissues. Arch Biochem Biophys 436: 50-61. (Pubitemid 40332424)
17. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, et al. (2009) Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 115: 243-250.
18. Fassnacht M, Johanssen S, Fenske W, Weismann D, Agha A, et al. (2010) Improved survival in patients with stage II adrenocortical carcinoma followed up prospectively by specialized centers. J Clin Endocrinol Metab 95: 4925-4932.
19. Nieman LK, Biller BM, Findling JW, Newell-Price J, Savage MO, et al. (2008) The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 93: 1526-1540. (Pubitemid 351656485)
20. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, et al. (2012) Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med 366: 2189-2197.
21. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45.
22. Ronchi CL, Leich E, Sbiera S, Weismann D, Rosenwald A, et al. (2012) Single nucleotide polymorphism microarray analysis in cortisol-secreting adrenocortical adenomas identifies new candidate genes and pathways. Neoplasia 14: 206-218.
23. Stenstedt K, Hallstrom M, Ledel F, Ragnhammar P, Ingelman-Sundberg M, et al. (2014) The expression of CYP2W1 in colorectal primary tumors, corresponding lymph node metastases and liver metastases. Acta Oncol.
24. Molina-Ortiz D, Camacho-Carranza R, Gonzalez-Zamora JF, Shalkow-Kalincovstein J, Cardenas-Cardos R, et al. (2014) Differential expression of cytochrome p450 enzymes in normal and tumor tissues from childhood rhabdomyosarcoma. PLoS One 9: e93261.
25. Ronchi CL, Sbiera S, Kraus L, Wortmann S, Johanssen S, et al. (2009) Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy. Endocr Relat Cancer 16: 907-918.
26. Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, et al. (2010) Towards a knowledge-based Human Protein Atlas. Nat Biotechnol 28: 1248-1250.
27. Nishida CR, Lee M, de Montellano PR (2010) Efficient hypoxic activation of the anticancer agent AQ4N by CYP2S1 and CYP2W1. Mol Pharmacol 78: 497-502.
28. Travica S, Pors K, Loadman PM, Shnyder SD, Johansson I, et al. (2013) Colon cancer-specific cytochrome P450 2W1 converts duocarmycin analogues into potent tumor cytotoxins. Clin Cancer Res 19: 2952-2961.
29. Sheldrake HM, Travica S, Johansson I, Loadman PM, Sutherland M, et al. (2013) Re-engineering of the Duocarmycin Structural Architecture Enables Bioprecursor Development Targeting CYP1A1 and CYP2W1 for Biological Activity. J Med Chem 56: 6273-6277.
30. Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab.
31. Else T, Williams AR, Sabolch A, Jolly S, Miller BS, et al. (2014) Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab 99: 455-461.
32. Volante M, Terzolo M, Fassnacht M, Rapa I, Germano A, et al. (2012) Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res 18: 3452-3461.
33. Cai W, Counsell RE, Schteingart DE, Sinsheimer JE, Vaz AD, et al. (1997) Adrenal proteins bound by a reactive intermediate of mitotane. Cancer Chemother Pharmacol 39: 537-540. (Pubitemid 27096770)
34. Schteingart DE, Sinsheimer JE, Benitez RS, Homan DF, Johnson TD, et al. (2012) Structural requirements for mitotane activity: development of analogs for treatment of adrenal cancer. Anticancer Res 32: 2711-2720.